What is Leerink Partnrs’ Forecast for Ardelyx Q3 Earnings?

Ardelyx, Inc. (NASDAQ:ARDX) – Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Ardelyx in a report released on Thursday, February 20th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical company will post earnings of ($0.03) per share for the quarter. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. Leerink Partnrs also issued estimates for Ardelyx’s Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at $0.40 EPS and FY2027 earnings at $1.00 EPS.

Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. The firm had revenue of $116.13 million during the quarter, compared to the consensus estimate of $111.16 million. Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%.

ARDX has been the subject of several other reports. Citigroup lowered their target price on shares of Ardelyx from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Raymond James reaffirmed a “strong-buy” rating and issued a $13.00 target price (down from $15.00) on shares of Ardelyx in a research note on Friday, February 21st. Cantor Fitzgerald raised shares of Ardelyx to a “strong-buy” rating in a research note on Thursday, January 30th. HC Wainwright reaffirmed a “neutral” rating and issued a $5.50 target price on shares of Ardelyx in a research note on Friday, February 21st. Finally, Piper Sandler boosted their price objective on shares of Ardelyx from $7.00 to $8.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.93.

Ardelyx Stock Up 1.0 %

ARDX stock opened at $5.18 on Monday. The stock has a market capitalization of $1.23 billion, a P/E ratio of -32.38 and a beta of 0.85. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.31 and a current ratio of 4.58. Ardelyx has a one year low of $4.32 and a one year high of $9.83. The company has a 50 day moving average price of $5.29 and a two-hundred day moving average price of $5.63.

Insider Activity at Ardelyx

In other Ardelyx news, CFO Justin A. Renz sold 5,171 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $5.62, for a total value of $29,061.02. Following the transaction, the chief financial officer now owns 285,968 shares in the company, valued at $1,607,140.16. The trade was a 1.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Laura A. Williams sold 4,941 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $5.62, for a total transaction of $27,768.42. Following the completion of the transaction, the insider now owns 303,804 shares in the company, valued at $1,707,378.48. This represents a 1.60 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 141,408 shares of company stock worth $761,963. 5.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ardelyx

A number of institutional investors have recently added to or reduced their stakes in the company. Heck Capital Advisors LLC acquired a new position in Ardelyx in the 4th quarter worth $121,000. Mackenzie Financial Corp raised its stake in shares of Ardelyx by 266.0% in the 4th quarter. Mackenzie Financial Corp now owns 140,133 shares of the biopharmaceutical company’s stock valued at $710,000 after purchasing an additional 101,841 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Ardelyx in the 4th quarter valued at about $25,000. Palisades Investment Partners LLC raised its stake in shares of Ardelyx by 7.1% in the 4th quarter. Palisades Investment Partners LLC now owns 517,781 shares of the biopharmaceutical company’s stock valued at $2,625,000 after purchasing an additional 34,432 shares in the last quarter. Finally, Two Seas Capital LP acquired a new stake in shares of Ardelyx in the 4th quarter valued at about $9,407,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.